ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical
Trending on TikTok(50,000+)

Semaglutide

Semaglutide

Also known as: Ozempic, Wegovy, GLP-1

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Semaglutide

Activates GLP-1 receptors in the hypothalamus to reduce appetite. Delays gastric emptying to promote satiety.

Dosing Information

Half-Life

~7 days

Typical Dose

0.25–2.4 mg

Frequency

Once weekly

Cycle Length

Ongoing / indefinite under medical supervision

Administration Routes:
subcutaneousoral

Benefits

  • Significant sustained weight loss (up to 15-17% body weight)
  • Improved glycemic control and insulin sensitivity
  • Reduced cardiovascular risk markers
  • Decreased appetite and food cravings
  • Improved blood pressure and lipid profiles

Side Effects

Nausea and vomiting (especially during dose titration)mild
Diarrhea or constipationmild
Abdominal pain and bloatingmild
Risk of pancreatitis (rare)mild
Potential gallbladder issuesmild

Mechanism of Action

1

Activates GLP-1 receptors in the hypothalamus to reduce appetite

2

Delays gastric emptying to promote satiety

3

Enhances glucose-dependent insulin secretion from pancreatic beta cells

4

Suppresses glucagon release to improve blood sugar regulation

Contraindications

Do not use this peptide if any of the following apply:

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2 (MEN2)
  • History of pancreatitis
  • Severe gastrointestinal disease

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

The STEP clinical trial programme demonstrated that semaglutide 2.4 mg weekly produces an average weight loss of approximately 15% of body weight over 68 weeks. The SELECT trial further showed a 20% reduction in major adverse cardiovascular events. FDA-approved for chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity.

Frequently Asked Questions

Common questions about Semaglutide

UK-Specific Information

Exclusive data points and guidance for UK residents using Semaglutide

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok